bibliometric analysis; biological products; CiteSpace; VOSviewer; trends

Rader RA. defining biopharmaceutical. Nature Biotechnology. 2008; 26(7): 743-751. doi: 10.1038/nbt0708-743 Blumenthal G. US Food and Drug Administration. J Thorac Oncol. 2019; 14(10): S37-S. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin‐associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008; 48(8): 1754-1762. doi: 10.1111/j.1537-2995.2008.01749.x Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2022; 82(1): 3-18. doi: 10.1136/ard-2022-223356 Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019; 78(6): 736-745. doi: 10.1136/annrheumdis-2019-215089 Perren TJ, Swart AM, Pfisterer J, et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine. 2011; 365(26): 2484-2496. doi: 10.1056/nejmoa1103799 Bronckers IMGJ, Paller AS, West DP, et al. A Comparison of Psoriasis Severity in Pediatric Patients Treated with Methotrexate vs Biologic Agents. JAMA Dermatology. 2020; 156(4): 384. doi: 10.1001/jamadermatol.2019.4835 Higgins CH. Biological products. Canadian Medical Association Journal. 1912; 2: 114-20. Barzman M, Bàrberi P, Birch ANE, et al. Eight principles of integrated pest management. Agronomy for Sustainable Development. 2015; 35(4): 1199-1215. doi: 10.1007/s13593-015-0327-9 Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of Clinical Oncology. 2015; 33(27): 3029-3035. doi: 10.1200/jco.2014.59.4895 Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. JAMA. 2018; 320(13): 1360. doi: 10.1001/jama.2018.13103 Capitanio U, Montorsi F. Renal cancer. Lancet. 2016; 387(10021): 894-906. doi: 10.1016/S0140-6736(15)00046-X Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clinic Proceedings. 2016; 91(3): 386-396. doi: 10.1016/j.mayocp.2015.12.017 van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology. 2013; 9(3): 164-172. doi: 10.1038/nrrheum.2013.4 Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Annals of the Rheumatic Diseases. 2017; 77(2): 175-187. doi: 10.1136/annrheumdis-2017-211555 Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019; 80(4): 1029-1072. doi: 10.1016/j.jaad.2018.11.057 Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases. 2019; 79(1): 19-30. doi: 10.1136/annrheumdis-2019-215672 Jacob JM, Karthik C, Saratale RG, et al. Biological approaches to tackle heavy metal pollution: A survey of literature. Journal of Environmental Management. 2018; 217: 56-70. doi: 10.1016/j.jenvman.2018.03.077 Gu Y, Yu L, Mou J, et al. Research Strategies to Develop Environmentally Friendly Marine Antifouling Coatings. Marine Drugs. 2020; 18(7): 371. doi: 10.3390/md18070371 Thapa Magar K, Boafo GF, Li X, et al. Liposome-based delivery of biological drugs. Chinese Chemical Letters. 2022; 33(2): 587-596. doi: 10.1016/j.cclet.2021.08.020 Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery. 2017; 16(12): 829-842. doi: 10.1038/nrd.2017.178 Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology. 2015; 68(1): 1-26. doi: 10.1002/art.39480 Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews Drug Discovery. 2014; 13(9): 655-672. doi: 10.1038/nrd4363 Fraenkel L, Bathon JM, England BR, et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021; 73(7): 924-939. doi: 10.1002/acr.24596 Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients with Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology. 2019; 17(9): 1655-1668. doi: 10.1016/j.cgh.2019.03.037 Solitano V, Facciorusso A, Jess T, et al. Comparative Risk of Serious Infections with Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2023; 21(4): 907-921.e2. doi: 10.1016/j.cgh.2022.07.032 Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opinion on Drug Safety. 2023; 22(1): 43-58. doi: 10.1080/14740338.2023.2173171 Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opinion on Drug Safety. 2023; 22(1): 25-41. doi: 10.1080/14740338.2023.2173170 Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clinical, Cosmetic and Investigational Dermatology. 2023; 16: 135-148. doi: 10.2147/ccid.s391356 Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study. Dermatologic Therapy. 2022; 35(7). doi: 10.1111/dth.15524 Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018; 16(1). doi: 10.1186/s12951-018-0392-8 Scioli Montoto S, Muraca G, Ruiz ME. Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. Frontiers in Molecular Biosciences. 2020; 7. doi: 10.3389/fmolb.2020.587997 Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease. Gastroenterology. 2020; 158(1): 189-199. doi: 10.1053/j.gastro.2019.09.041 Levy-Clarke G, Jabs DA, Read RW, et al. Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology. 2014; 121(3): 785-796.e3. doi: 10.1016/j.ophtha.2013.09.048 Sandborn WJ, Panés J, D’Haens GR, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clinical Gastroenterology and Hepatology. 2019; 17(8): 1541-1550. doi: 10.1016/j.cgh.2018.11.035 St.Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 2002; 46(6): 1451-1459. doi: 10.1002/art.10302 Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2014; 64(10): 1539-1545. doi: 10.1136/gutjnl-2014-307883 Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients with Ulcerative Colitis. Gastroenterology. 2014; 147(6): 1296-1307.e5. doi: 10.1053/j.gastro.2014.08.035 Ma C, Battat R, Jairath V, et al. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology. 2019; 17(1): 127-145. doi: 10.1007/s11938-019-00222-9 Papamichael K, Vogelzang EH, Lambert J, et al. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Review of Clinical Immunology. 2019; 15(8): 837-848. doi: 10.1080/1744666x.2019.1630273 Medina F, Plasencia C, Goupille P, et al. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. Therapeutic Drug Monitoring. 2017; 39(4): 364-369. doi: 10.1097/ftd.0000000000000421 Nagase H, Suzukawa M, Oishi K, et al. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergology International. 2023; 72(1): 11-23. doi: 10.1016/j.alit.2022.11.008 Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients with Inflammatory Bowel Disease with Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021; 161(3): 827-836. doi: 10.1053/j.gastro.2021.05.044 Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Frontiers in Pharmacology. 2021; 12. doi: 10.3389/fphar.2021.601626 Pettinari C, Pettinari R, Di Nicola C, et al. Antimicrobial MOFs. Coordination Chemistry Reviews. 2021; 446: 214121. doi: 10.1016/j.ccr.2021.214121 Castellano JM, Ramos-Romero S, Perona JS. Oleanolic Acid: Extraction, Characterization and Biological Activity. Nutrients. 2022; 14(3): 623. doi: 10.3390/nu14030623 Azadeh H, Alizadeh-Navaei R, Rezaiemanesh A, et al. Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. Inflammopharmacology. 2022; 30(2): 435-451. doi: 10.1007/s10787-022-00933-z Kozma GT, Shimizu T, Ishida T, et al. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Advanced Drug Delivery Reviews. 2020; 154-155: 163-175. doi: 10.1016/j.addr.2020.07.024 Rathore AS, Nikita S, Thakur G, et al. Artificial intelligence and machine learning applications in biopharmaceutical manufacturing. Trends in Biotechnology. 2023; 41(4): 497-510. doi: 10.1016/j.tibtech.2022.08.007